Sanofi (NASDAQ:SNY) Shares Gap Up – Should You Buy?

Sanofi (NASDAQ:SNY)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $45.89, but opened at $47.65. Sanofi shares last traded at $47.85, with a volume of 453,757 shares trading hands.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Sanofi presently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Trading Up 6.4 %

The firm has a 50 day simple moving average of $50.84 and a 200 day simple moving average of $52.09. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $123.95 billion, a PE ratio of 24.96, a P/E/G ratio of 1.23 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. Sanofi’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same period last year, the company earned $2.55 EPS. Equities analysts expect that Sanofi will post 4.06 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sanofi

Institutional investors and hedge funds have recently modified their holdings of the company. Barrow Hanley Mewhinney & Strauss LLC raised its stake in Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after acquiring an additional 3,164,092 shares during the period. Magnetar Financial LLC increased its stake in Sanofi by 1,153.1% in the 2nd quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock worth $121,605,000 after buying an additional 2,306,286 shares in the last quarter. Jennison Associates LLC raised its holdings in Sanofi by 938.0% during the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock valued at $109,753,000 after acquiring an additional 1,720,972 shares during the period. Thrivent Financial for Lutherans boosted its stake in shares of Sanofi by 28,890.2% in the third quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock worth $82,366,000 after acquiring an additional 1,424,289 shares during the period. Finally, Bank of New York Mellon Corp grew its position in shares of Sanofi by 19.0% during the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after purchasing an additional 1,370,232 shares in the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.